Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C)
- PMID: 12445863
- DOI: 10.1016/s0006-2952(02)01456-9
Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C)
Abstract
Previously, we reported that two distinct in vitro tumor cell models of hypoxia (Models A and B) are hypersensitive to glycolytic inhibitors such as 2-deoxy-D-glucose (2-DG) and oxamate [Liu et al., Biochemistry 2001;40:5542-7]. Model A consists of osteosarcoma cells (143B) treated with agents that interfere with mitochondrial oxidative phosphorylation (OxPhos), and Model B represents rho(0) cells, a variant derived from 143B cells, which, due to their deficiency in mitochondrial DNA, cannot perform OxPhos. Extending these studies, we report here on Model C, which is composed of 143B cells grown under various levels of external O(2) (0, 0.1, 0.5, 1, 5, 10, and 21%). At the lower levels of O(2) that we tested, 143B cells were hypersensitive to 2-DG and oxamate when compared with cells grown at a normal level of O(2). In contrast, 143B cells under hypoxic or aerobic conditions showed equal sensitivity to a standard chemotherapeutic agent, vinblastine. Furthermore, when treated under reduced O(2) amounts, rho(0) cells displayed no hypersensitivity to 2-DG and, in fact, were slightly more resistant than under aerobic conditions. At 0-5% O(2) levels, untreated 143B cells displayed reduced growth and elevated lactic acid levels, while rho(0) cell growth remained unaffected except at 0% O(2) where growth was inhibited by 19%. The results with Model C are in agreement with our previous data using Models A and B, and extend these studies by illustrating that within a wide range of hypoxia the growth of tumor cells is retarded and that these slow-growing cells become hypersensitized to glycolytic inhibitors. Taken together with Models A and B, the data with Model C support our hypothesis that the hypoxic environment of slow-growing cells found in the inner core of solid tumors renders them amenable to selective targeting with glycolytic inhibitors.
Copyright 2002 Elsevier Science Inc.
Similar articles
-
Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions.Cancer Chemother Pharmacol. 2004 Feb;53(2):116-22. doi: 10.1007/s00280-003-0724-7. Epub 2003 Nov 7. Cancer Chemother Pharmacol. 2004. PMID: 14605866
-
Hypersensitization of tumor cells to glycolytic inhibitors.Biochemistry. 2001 May 8;40(18):5542-7. doi: 10.1021/bi002426w. Biochemistry. 2001. PMID: 11331019
-
Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose.Mol Cancer Ther. 2007 Feb;6(2):732-41. doi: 10.1158/1535-7163.MCT-06-0407. Mol Cancer Ther. 2007. PMID: 17308069
-
Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells.Antioxid Redox Signal. 2007 Sep;9(9):1383-90. doi: 10.1089/ars.2007.1714. Antioxid Redox Signal. 2007. PMID: 17627467 Review.
-
From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors.Mol Nutr Food Res. 2009 Jan;53(1):68-75. doi: 10.1002/mnfr.200700457. Mol Nutr Food Res. 2009. PMID: 19072739 Free PMC article. Review.
Cited by
-
Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors.Clin Ophthalmol. 2012;6:817-30. doi: 10.2147/OPTH.S29688. Epub 2012 May 29. Clin Ophthalmol. 2012. PMID: 22701083 Free PMC article.
-
Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning.Cancer Cell Int. 2011 Feb 14;11:3. doi: 10.1186/1475-2867-11-3. Cancer Cell Int. 2011. PMID: 21320311 Free PMC article.
-
Metabolic Phenotype Intricacies on Altered Glucose Metabolism of Breast Cancer Cells upon Glut-1 Inhibition and Mimic Hypoxia In Vitro.Appl Biochem Biotechnol. 2023 Oct;195(10):5838-5854. doi: 10.1007/s12010-023-04373-5. Epub 2023 Jan 28. Appl Biochem Biotechnol. 2023. PMID: 36708494
-
Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model.J Cancer Res Clin Oncol. 2011 Jan;137(1):65-72. doi: 10.1007/s00432-010-0860-5. Epub 2010 Mar 25. J Cancer Res Clin Oncol. 2011. PMID: 20336315
-
Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells.BMC Pharmacol Toxicol. 2019 May 3;20(1):22. doi: 10.1186/s40360-019-0301-2. BMC Pharmacol Toxicol. 2019. PMID: 31053173 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources